Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Pediatric Sedated Bronchoscopy

Sponsor
Zhejiang University
Study ID
NCT07563075
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Hypoxemia
  • Pneumonia
  • Pulmonary Neoplasm

Eligibility Criteria

Sex
ALL
Age
1 Year - 6 Years
Healthy Volunteers
Not accepted

Interventions

  • High-flow nasal cannula — DEVICE
    Using High-flow nasal cannula oxygenation
  • Regular Nasal Cannula — DEVICE
    Using regular nasal cannula for oxygenation

Study Details

Due to children's lower oxygen reserves and higher oxygen consumption, sedation can easily lead to respiratory adverse events such as hypoxemia. It has been reported that the incidence of hypoxemia during pediatric bronchoscopy is high, highlighting that hypoxemia in pediatric painless bronchoscopy is an urgent problem requiring a solution. High-flow nasal cannula (HFNC) oxygen therapy delivers heated and humidified breathing gas with a precisely controllable oxygen concentration, at flow rates exceeding the patient's peak inspiratory flow, directly via unsealed nasal prongs. It is a simple, comfortable, effective, and non-invasive respiratory support method that has been widely adopted in clinical practice. However, the effectiveness of HFNC in pediatric sedation remains unclear. Therefore, this multicenter randomized controlled trial aims to evaluate whether HFNC can effectively reduce the occurrence of hypoxemia during sedated bronchoscopy in pediatric patients.

Key Dates

First listed
May 1, 2026
Start date
Apr 1, 2026
Status verified
Mar 2026
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
430 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: High-flow nasal cannula Group
  • Active Comparator: Regular Nasal Cannula Group

Primary Outcome Measure

The incidence of hypoxemia [ Time Frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours ]

Central Contacts

Related Studies